Body Girdles

On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will probably under no circumstances disappear and a vaccine will not quit it completely. He also mentioned that ministers and authorities really should cease ‘over-promising’ and be realistic about the prospects of a vaccine and the likely timeline of one particular, unlikely ahead of spring subsequent year.

He then echoed his earlier warnings and these of his colleague Professor Chris Whitty that the COVID-19 fight will be a lengthy one, and it will be with us for fantastic.

So, from this really should we assume there is no ‘silver bullet’ for COVID-19 infections?

What if there have been a single therapy that:

could stop the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in situations where individuals developed secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug currently established as protected
was simple to make, scalable at the level essential to make a distinction in the pandemic and was cost efficient, then wouldn’t that be something we should all be obtaining excited about?
Certainly although no such ‘silver bullet’ game changing therapy exists? Just after all, the only remedies we hear about for COVID are these which President Trump took, which have been either incredibly new, high-priced and experimental or have a quite narrow application to a certain aspect of the illness.
Well, you heard it right here very first – such a ‘silver bullet’ treatment does exist right now. It is called Nylexa®, from the compact UK biotech firm NovaBiotics Ltd. It’s active components have been safely utilised in medicines that treat unrelated circumstances for more than 30 years.

NovaBiotics found Nylexa’s prospective positive aspects in COVID-19 following a decade of study in tricky to treat, drug-resistant infections, which includes the complicated chest infections and inflammation associated with cystic fibrosis (CF) lung illness. In March they applied for a £1m grant from Innovate UK (representing the government) to get started clinical research. That grant was at some point awarded earlier this month, and the government are now thinking of whether or not to incorporate Nylexa on two separate NHS platform studies.

But why, I hear you ask, if this is so fantastic have we not heard about it before? Why are the government and the press not shouting about this from the rooftops? Why is this not getting demanded by clinicians desperate for successful remedies for their sufferers?

I am afraid to say, it all boils down to income. Tiny biotech businesses uncover it challenging to get focus as they don’t have the resources out there to their bigger much better funded rivals. The names we read about routinely when it comes to ground breaking new treatments are invariably big multi-national pharmaceutical firms with deep pockets and big budgets to market their own specific wares. They make confident their drugs get the essential interest. NovaBiotics is a little private firm funded by a group of loyal and supportive shareholders so unfortunately don’t have the resources to compete for interest with the huge boys.

Which is why this scenario is so frustrating. In mitigating the overall health consequences of contracting COVID-19, Nylexa® could raise public self-confidence of living with the virus for the longer term and potentially allow a higher degree of normality to return to the way in which we live, benefiting the economy directly in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. But having people today in positions of influence to take notice amongst all the others competing for their attention is pretty tricky indeed.

rapid covid testing near me is reported that there are thousands of possible COVID-19 remedies in clinical trials across the world. I would challenge any individual to show me one particular which has the same possible for optimistic influence as Nylexa®, yet this is not currently element of any trial, despite its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials right away. The sooner it gets tested, the sooner it can be applied to help sort out the mess the pandemic has triggered to all our lives.

About NovaBiotics Ltd

NovaBiotics Ltd is a clinical-stage biotechnology corporation focused on the design and development of 1st-in-class therapies for difficult-to-treat, medically unmet infectiousdiseases caused by bacteria and fungi and respiratory circumstances like cystic fibrosis and COVID-19.

A leading innovator in the anti-infectives space, the Company’s robust technologies and company model has been validated by way of productive development, from notion to late stage clinical improvement, of its most advanced solution candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, higher-worth drug candidates such as NP339 (Division of Wellness and Social Care funded programme) for life threatening, drug resistant invasive fungal disease and NP432 for multi- drug resistant bacterial infections.